Alnylam Pharmaceuticals Inc
ALNY
View Detailed Chart
331.371USD
+23.321+7.57%
Market hours （ET）Quotes delayed by 15 min
17.20BMarket Cap
138.36P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+7.57%
5 Days
+5.26%
1 Month
+1.23%
6 Months
-26.29%
Year to Date
-16.67%
1 Year
+17.94%
View Detailed Chart
TradingKey Stock Score of Alnylam Pharmaceuticals Inc
Currency: USD Updated: 2026-03-25Key Insights
Alnylam Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 9 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 445.97.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alnylam Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Alnylam Pharmaceuticals Inc Highlights
StrengthsRisks
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 103.14% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 137.25, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 132.38M shares, decreasing 0.01% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 2.06K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.39.
Analyst Rating
Based on
30
analysts
Buy
Current Rating
445.971
Target Price
+45.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Alnylam Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alnylam Pharmaceuticals Inc Info
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Ticker SymbolALNY
CompanyAlnylam Pharmaceuticals Inc
CEOGreenstreet (Yvonne L)
Websitehttps://www.alnylam.com/
Related Instruments
-1.52%
-0.38%
+2.54%
-1.14%
+2.60%
+2.02%
+1.15%
+1.32%
-1.23%
+2.50%
+1.02%
+3.55%
+2.80%
+3.29%
+0.40%
0.00%
+2.56%
+0.48%
+1.61%
+0.64%Popular Symbols
254.760
+2.140 (+0.85%)
172.165
-6.515 (-3.65%)
68287.450
-2692.050 (-3.79%)
274.020
-22.120 (-7.47%)
2039.440
-124.550 (-5.76%)
375.270
-10.680 (-2.77%)
4376.260
-129.180 (-2.87%)
94.202
+3.263 (+3.59%)
1.153
-0.003 (-0.25%)
159.790
+0.331 (+0.21%)
